82 related articles for article (PubMed ID: 7613559)
1. Dose response studies. II. Analysis and interpretation.
Ruberg SJ
J Biopharm Stat; 1995 Mar; 5(1):15-42. PubMed ID: 7613559
[TBL] [Abstract][Full Text] [Related]
2. Dose response studies. I. Some design considerations.
Ruberg SJ
J Biopharm Stat; 1995 Mar; 5(1):1-14. PubMed ID: 7613556
[TBL] [Abstract][Full Text] [Related]
3. Factorial dose-response studies using frequency and magnitude of dose.
Hafner KB; Ruberg SJ
J Biopharm Stat; 1996 Jul; 6(3):253-62. PubMed ID: 8854230
[TBL] [Abstract][Full Text] [Related]
4. A multiple comparison procedure to control the strong stagewise family error rate in comparing test treatments and a control.
Chen M; Kianifard F
J Biopharm Stat; 1997 Jul; 7(3):355-67. PubMed ID: 9252830
[TBL] [Abstract][Full Text] [Related]
5. Identifying the maximum safe dose: a multiple testing approach.
Hothorn LA; Hauschke D
J Biopharm Stat; 2000 Feb; 10(1):15-30. PubMed ID: 10709798
[TBL] [Abstract][Full Text] [Related]
6. Application of response surface methodology and factorial designs to clinical trials for drug combination development.
Stewart WH
J Biopharm Stat; 1996 Jul; 6(3):219-30. PubMed ID: 8854227
[TBL] [Abstract][Full Text] [Related]
7. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
[TBL] [Abstract][Full Text] [Related]
8. Using the partitioning principle to adaptively design dose-response studies.
Ling X; Hsu J
J Biopharm Stat; 2006; 16(5):733-43. PubMed ID: 17037268
[TBL] [Abstract][Full Text] [Related]
9. Non-parametric estimators of a monotonic dose-response curve and bootstrap confidence intervals.
Dilleen M; Heimann G; Hirsch I
Stat Med; 2003 Mar; 22(6):869-82. PubMed ID: 12627406
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension.
Germino FW
Clin Ther; 2009 Sep; 31(9):1946-56. PubMed ID: 19843484
[TBL] [Abstract][Full Text] [Related]
11. Identifying effective and/or safe doses by stepwise confidence intervals for ratios.
Bretz F; Hothorn LA; Hsu JC
Stat Med; 2003 Mar; 22(6):847-58. PubMed ID: 12627404
[TBL] [Abstract][Full Text] [Related]
12. Statistical methods for a three-period crossover design in which high dose cannot be used first.
Peace KE; Koch GG
J Biopharm Stat; 1993 Mar; 3(1):103-16. PubMed ID: 8485531
[TBL] [Abstract][Full Text] [Related]
13. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
14. Imputation strategies for missing continuous outcomes in cluster randomized trials.
Taljaard M; Donner A; Klar N
Biom J; 2008 Jun; 50(3):329-45. PubMed ID: 18537126
[TBL] [Abstract][Full Text] [Related]
15. A practical limit to trials needed in one-person randomized controlled experiments.
Alemi R; Alemi F
Qual Manag Health Care; 2007; 16(2):130-4. PubMed ID: 17426611
[TBL] [Abstract][Full Text] [Related]
16. The analysis of a multiple-dose, combination-drug clinical trial using response surface methodology.
Phillips JA; Cairns V; Koch GG
J Biopharm Stat; 1992; 2(1):49-67. PubMed ID: 1300205
[TBL] [Abstract][Full Text] [Related]
17. Dose finding - a challenge in statistics.
Bretz F; Hsu J; Pinheiro J; Liu Y
Biom J; 2008 Aug; 50(4):480-504. PubMed ID: 18663758
[TBL] [Abstract][Full Text] [Related]
18. How to deal with multiple treatment or dose groups in randomized clinical trials?
Hothorn LA
Fundam Clin Pharmacol; 2007 Apr; 21(2):137-54. PubMed ID: 17391286
[TBL] [Abstract][Full Text] [Related]
19. A logistic dose-ranging method for phase I clinical investigations trials.
Murphy JR; Hall DL
J Biopharm Stat; 1997 Nov; 7(4):635-47. PubMed ID: 9358335
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials.
Shuhendler AJ; Lee S; Siu M; Ondovcik S; Lam K; Alabdullatif A; Zhang X; Machado M; Einarson TR
Pharmacotherapy; 2009 Jul; 29(7):784-91. PubMed ID: 19558252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
